Cargando…
SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination
(1) Background: SARS-CoV-2 T cell immunity is rapidly activated following SARS-CoV-2 infection and vaccination and is crucial for controlling infection progression and severity. The aim of the present study was to compare the levels of T cell responses to SARS-CoV-2 between cohorts of subjects with...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384199/ https://www.ncbi.nlm.nih.gov/pubmed/37515000 http://dx.doi.org/10.3390/vaccines11071186 |
_version_ | 1785081099154620416 |
---|---|
author | Pitiriga, Vassiliki C. Papamentzelopoulou, Myrto Konstantinakou, Kanella E. Theodoridou, Kalliopi Vasileiou, Irene V. Tsakris, Athanasios |
author_facet | Pitiriga, Vassiliki C. Papamentzelopoulou, Myrto Konstantinakou, Kanella E. Theodoridou, Kalliopi Vasileiou, Irene V. Tsakris, Athanasios |
author_sort | Pitiriga, Vassiliki C. |
collection | PubMed |
description | (1) Background: SARS-CoV-2 T cell immunity is rapidly activated following SARS-CoV-2 infection and vaccination and is crucial for controlling infection progression and severity. The aim of the present study was to compare the levels of T cell responses to SARS-CoV-2 between cohorts of subjects with hybrid immunity (convalescent and vaccinated), vaccinated naïve (non-exposed) and convalescent unvaccinated subjects. (2) Methods: We performed a retrospective descriptive analysis of data collected from the medical records of adult individuals who were consecutively examined at a large, private Medical Center of Attica from September 2021 to September 2022 in order to be examined on their own initiative for SARS-CoV-2 T cell immunity response. They were divided into three groups: Group A: SARS-CoV-2 convalescent and vaccinated subjects; Group B: SARS-CoV-2 naïve vaccinated subjects; Group C: SARS-CoV-2 convalescent unvaccinated subjects. The SARS-CoV-2 T cell response was estimated against spike (S) and nucleocapsid (N) structural proteins by performing the methodology T-SPOT.COVID test. (3) Results: A total of 530 subjects were retrospectively included in the study, 252 females (47.5%) and 278 (52.5%) males ranging from 13 to 92 years old (mean 55.68 ± 17.0 years). Among them, 66 (12.5%) were included in Group A, 284 (53.6%) in Group B and 180 (34.0%) in Group C. Among the three groups, a reaction against S antigen was reported in 58/66 (87.8%) of Group A, 175/284 (61.6%) of Group B and 146/180 (81.1%) of Group C (chi-square, p < 0.001). Reaction against N antigen was present in 49/66 (74.2%) of Group A and in 140/180 (77.7%) of Group C (chi-square, p = 0.841). The median SFC count for S antigen was 24 (range from 0–218) in Group A, 12 (range from 0–275) in Group B and 18 (range from 0–160) in Group C (Kruskal–Wallis test, p < 0.001; pairwise comparisons: groups A–B, p < 0.001; groups A–C, p = 0.147; groups B–C, p < 0.001). The median SFCs count for N antigen was 13 (range 0–82) for Group A and 18 (range 0–168) for Group C (Kruskal–Wallis test, p = 0.27 for A–C groups). (4) Conclusions: Our findings suggest that natural cellular immunity, either alone or combined with vaccination, confers stronger and more durable protection compared to vaccine-induced cellular immunity. |
format | Online Article Text |
id | pubmed-10384199 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103841992023-07-30 SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination Pitiriga, Vassiliki C. Papamentzelopoulou, Myrto Konstantinakou, Kanella E. Theodoridou, Kalliopi Vasileiou, Irene V. Tsakris, Athanasios Vaccines (Basel) Article (1) Background: SARS-CoV-2 T cell immunity is rapidly activated following SARS-CoV-2 infection and vaccination and is crucial for controlling infection progression and severity. The aim of the present study was to compare the levels of T cell responses to SARS-CoV-2 between cohorts of subjects with hybrid immunity (convalescent and vaccinated), vaccinated naïve (non-exposed) and convalescent unvaccinated subjects. (2) Methods: We performed a retrospective descriptive analysis of data collected from the medical records of adult individuals who were consecutively examined at a large, private Medical Center of Attica from September 2021 to September 2022 in order to be examined on their own initiative for SARS-CoV-2 T cell immunity response. They were divided into three groups: Group A: SARS-CoV-2 convalescent and vaccinated subjects; Group B: SARS-CoV-2 naïve vaccinated subjects; Group C: SARS-CoV-2 convalescent unvaccinated subjects. The SARS-CoV-2 T cell response was estimated against spike (S) and nucleocapsid (N) structural proteins by performing the methodology T-SPOT.COVID test. (3) Results: A total of 530 subjects were retrospectively included in the study, 252 females (47.5%) and 278 (52.5%) males ranging from 13 to 92 years old (mean 55.68 ± 17.0 years). Among them, 66 (12.5%) were included in Group A, 284 (53.6%) in Group B and 180 (34.0%) in Group C. Among the three groups, a reaction against S antigen was reported in 58/66 (87.8%) of Group A, 175/284 (61.6%) of Group B and 146/180 (81.1%) of Group C (chi-square, p < 0.001). Reaction against N antigen was present in 49/66 (74.2%) of Group A and in 140/180 (77.7%) of Group C (chi-square, p = 0.841). The median SFC count for S antigen was 24 (range from 0–218) in Group A, 12 (range from 0–275) in Group B and 18 (range from 0–160) in Group C (Kruskal–Wallis test, p < 0.001; pairwise comparisons: groups A–B, p < 0.001; groups A–C, p = 0.147; groups B–C, p < 0.001). The median SFCs count for N antigen was 13 (range 0–82) for Group A and 18 (range 0–168) for Group C (Kruskal–Wallis test, p = 0.27 for A–C groups). (4) Conclusions: Our findings suggest that natural cellular immunity, either alone or combined with vaccination, confers stronger and more durable protection compared to vaccine-induced cellular immunity. MDPI 2023-06-30 /pmc/articles/PMC10384199/ /pubmed/37515000 http://dx.doi.org/10.3390/vaccines11071186 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pitiriga, Vassiliki C. Papamentzelopoulou, Myrto Konstantinakou, Kanella E. Theodoridou, Kalliopi Vasileiou, Irene V. Tsakris, Athanasios SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination |
title | SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination |
title_full | SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination |
title_fullStr | SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination |
title_full_unstemmed | SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination |
title_short | SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination |
title_sort | sars-cov-2 t cell immunity responses following natural infection and vaccination |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384199/ https://www.ncbi.nlm.nih.gov/pubmed/37515000 http://dx.doi.org/10.3390/vaccines11071186 |
work_keys_str_mv | AT pitirigavassilikic sarscov2tcellimmunityresponsesfollowingnaturalinfectionandvaccination AT papamentzelopouloumyrto sarscov2tcellimmunityresponsesfollowingnaturalinfectionandvaccination AT konstantinakoukanellae sarscov2tcellimmunityresponsesfollowingnaturalinfectionandvaccination AT theodoridoukalliopi sarscov2tcellimmunityresponsesfollowingnaturalinfectionandvaccination AT vasileiouirenev sarscov2tcellimmunityresponsesfollowingnaturalinfectionandvaccination AT tsakrisathanasios sarscov2tcellimmunityresponsesfollowingnaturalinfectionandvaccination |